Celgene 4 Molecular

Complete response rates were observed consistently across patient subgroups in those with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

A recommendation from an independent data monitoring committee prompted the discontinuation of the phase 3 CAPItello-280 trial.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Data show that patients who undergo grade group 1 prostatectomies may experience an increased likelihood of higher risk features.

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.